Ariel Hurley Sells 1,819 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 1,819 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the transaction, the insider now owns 14,967 shares in the company, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Blueprint Medicines Stock Down 4.9 %

Shares of BPMC opened at $91.78 on Thursday. The stock has a 50 day moving average price of $92.41 and a 200 day moving average price of $97.29. Blueprint Medicines Co. has a one year low of $72.24 and a one year high of $121.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The stock has a market capitalization of $5.83 billion, a price-to-earnings ratio of -43.50 and a beta of 0.59.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. The business had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company’s revenue for the quarter was up 126.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.20) earnings per share. Equities research analysts forecast that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Quarry LP acquired a new stake in shares of Blueprint Medicines in the third quarter valued at approximately $32,000. Covestor Ltd increased its stake in shares of Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 403 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Blueprint Medicines during the 3rd quarter worth $108,000. CWM LLC boosted its position in shares of Blueprint Medicines by 114.6% during the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 590 shares during the last quarter. Finally, Van ECK Associates Corp grew its holdings in shares of Blueprint Medicines by 13.3% in the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 131 shares during the period.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, November 15th. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Wells Fargo & Company decreased their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Finally, JPMorgan Chase & Co. assumed coverage on Blueprint Medicines in a report on Thursday, November 14th. They set an “overweight” rating and a $126.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.11.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.